HUM - Humana Inc
Executive Summary
Humana Inc is a US healthcare insurer headquartered in the United States, organised under the sector classification Healthcare and the industry designation Medical - Healthcare Plans. The company is one of the largest Medicare Advantage (MA) managed care organisations in the country, providing MAPD and standalone Prescription Drug Plan (PDP) products to Medicare-eligible seniors, alongside commercial, Medicaid, and military health coverage. Its market position is concentrated in the MA segment, where it competes with UnitedHealth, Elevance Health, CVS Health (Aetna), and Cigna.
The investment case rests on a single hard catalyst - the next scheduled quarterly earnings release, due on 29 July 2026 (per a third-party earnings calendar referencing 2026-07-29 as the report date, before the market open), which should confirm whether Q2 2026 momentum continues after the Q1 2026 print and whether membership growth guidance has stabilised. To work, the call needs three things to hold: MA reimbursement rates that do not deteriorate beyond what is already in guidance, Stars ratings that hold at current bonus-qualifying levels, and a medical benefit ratio that does not re-accelerate higher. The primary risk is that CMS rate pressure or a Stars downgrade directly impairs earnings in 2027, which the filing-disclosed reimbursement and MCR exposure makes a credible scenario.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would shift to a more constructive stance on confirmed Stars retention and a step-up in 2027 MA membership guidance, and would degrade to a Reduce on a Q2 2026 earnings miss combined with affirmed or lowered full-year EPS.
Business Model
Humana generates the majority of its revenue through capitated contracts with the US Centres for Medicare and Medicaid Services (CMS), under which it receives a fixed per-member per-month (PMPM) premium for providing health benefits to Medicare-eligible seniors enrolled in MA plans. Premium revenues are risk-adjusted based on member demographics and health status, with the company bearing the medical cost risk and earning the spread between premium income and benefits expense. Additional revenue is generated from member premiums, commercial group plans, Medicaid managed care contracts at the state level, and the Tricare military health programme. Q1 FY26 reported revenue of 39.65bn USD and earnings of 1.24bn USD per public market data, with the trailing twelve months shown at a 7.59% return against the S&P 500's 3.34% over the same window.
The profitability of the model is governed primarily by the medical benefit ratio (MBR), which represents benefits expense as a percentage of premium revenue, and by Stars ratings from CMS, which drive quality bonus payments - 4-star plans receive a 5% quality bonus on base premium, while 5-star plans can receive up to an additional 3% bonus. Higher Stars also enable year-round marketing and enrolment, which materially supports membership growth. Humana's competitive moat, to the extent one exists, rests on its MA scale, its integrated CentreWell primary care and home health platforms, and its proprietary CarePoint provider engagement infrastructure, all of which are designed to manage utilisation and chronic disease in a capitated environment.
The customer base is split between individual Medicare beneficiaries enrolling directly or via brokers, employer groups purchasing commercial coverage, state Medicaid agencies, and the US Department of Defence for the Tricare programme. Mix is heavily weighted toward MA, with Medicaid and military health as secondary pillars. The model is sensitive to two policy levers - the CMS MA rate notice issued each year, and the Stars quality bonus programme - which together determine a large share of revenue per member.
Financial Snapshot
Recent Catalysts
[Q1 FY26, reported April 2026] - Humana reported Q1 FY26 revenue of 39.65bn USD and earnings of 1.24bn USD per publicly aggregated market data, a quarter referenced in subsequent commentary as having lowered the 2026 EPS outlook alongside announced buybacks. Source: Yahoo Finance / Simply Wall St aggregator commentary.
[5 May 2026] - A CNBC report on Q1 2026 earnings across major US managed care names stated that insurers including Humana are recovering, while flagging that the next quarter would be especially key for Humana given its expectation of Medicare Advantage membership growth. Source: CNBC.
[2026-07-29] - Humana is scheduled to report its next quarterly earnings before the market open on 29 July 2026, per a third-party earnings calendar. Source: ChartMill earnings calendar.
[April 2026] - Humana posted a Q2 2025 (referenced in the earnings call transcript dated April 2026) where management indicated 2026 benefits are largely stable in some areas with selective investment and pullback in others. Source: Motley Fool earnings call transcript (Q2 2025 transcript, dated April 2026).
Thesis Evaluation
Bull Case (25% weight)
MA membership re-accelerates beyond 2026 guidance on the back of stable CMS rates and held Stars ratings, Q2 2026 earnings (due 29 July 2026) affirm full-year EPS and signal 2027 margin recovery, and CentreWell drives an incremental margin tailwind. Under those conditions a re-rating toward the high end of the historical MA payer range is supportable over a 12-month horizon, with a target of USD 430 by mid-2027.
Base Case (50% weight)
Guidance is reaffirmed but not raised at the 29 July 2026 print, Stars ratings hold at current bonus-qualifying levels, and the medical benefit ratio normalises modestly from elevated 2025 levels without a step-change improvement. EPS growth tracks mid-single digits and the shares trade broadly sideways on fundamentals, with any upside driven by sector rotation rather than company-specific catalysts, yielding a 12-month target of USD 360.
Bear Case (25% weight)
CMS issues a more adverse MA rate notice than expected, a Stars downgrade removes a meaningful slice of quality bonus revenue, and the medical benefit ratio re-accelerates as utilisation trends higher, compressing 2027 EPS by a low-double-digit percentage. In that scenario the multiple compresses and downside targets a return toward prior-cycle lows, with a 12-month target of USD 220.
Key Risks
- CMS Medicare Advantage rate pressure: An adverse MA rate notice from CMS reduces revenue per member and pressures the medical benefit ratio. Estimated probability: 40%. Impact: severe.
- Stars ratings downgrade: A drop below 4 Stars removes the 5% quality bonus and curtails year-round marketing, directly impairing premium revenue per member. Estimated probability: 25%. Impact: severe.
- Medical cost ratio re-acceleration: Rising utilisation and acuity push the MCR higher, compressing underwriting margin. Estimated probability: 45%. Impact: moderate.
- Valuation risk: The trailing P/E around 34x prices in execution that the affirmed guidance does not yet support. Estimated probability: 50%. Impact: moderate.
- Medicaid contract concentration: State contract losses, including the Illinois contract being cited as a recent win, expose the segment to procurement risk. Estimated probability: 20%. Impact: low.
Who Should Own It / Avoid It
Ideal for: long-term investors with a 12-24 month horizon, a moderate-to-high risk tolerance, and existing exposure to US healthcare who want managed-care diversification alongside UnitedHealth, Elevance, CVS, and Cigna. The position suits investors who can tolerate policy-driven drawdowns of 20-30% on CMS rate headlines and who believe MA scale and Stars retention are defensible competitive advantages.
Avoid if: you require a near-term catalyst-driven trade, are unwilling to underwrite policy and regulatory risk, or have a low tolerance for single-stock drawdowns in the high-teens to low-twenties percentage range. Investors who need current-year EPS acceleration or who are averse to a forward P/E around 34x should not own this name at the current price.
Recommendation
OPPORTUNISTIC BUY - 59/100. The tier reflects a balanced risk-reward where hard Q1 2026 momentum and the scheduled 29 July 2026 earnings check are partially offset by a stretched valuation and credible MA reimbursement and Stars risks already disclosed in filings. The call would upgrade to a stronger buy on a Q2 2026 beat with raised 2027 membership or margin guidance, and would degrade to Reduce on a Q2 2026 miss with affirmed or lowered full-year EPS, or on an adverse CMS rate notice for 2027. At the current price of $363.86 the shares trade at or above our base-case target of $360.00: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above $266.67.
The probability-weighted value across our three scenarios is $342.50, 6% below the current price of $363.86 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $266.67 - below this level the upside to the base-case target ($360.00) is at least 2x the downside to the bear case ($220.00), the minimum risk/reward we require before committing new capital.
between $266.67 and $360.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $360.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A confirmed CMS Stars downgrade below 4 stars for a material share of MA membership, combined with an adverse 2027 MA rate notice that lowers 2027 EPS guidance by 10% or more, regardless of price - the bear target of $220.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Down.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 43 |
| 2026-06-28 | 43 |
| 2026-05-30 | 34 |
| 2026-04-28 | 68 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow including CNBC earnings coverage, Yahoo Finance quote and history pages, MarketBeat earnings calendar entries, Motley Fool earnings call transcripts, Simply Wall St aggregator commentary, and third-party earnings calendars referencing the 29 July 2026 report date.
Primary source types: SEC filings and Form 4 insider activity disclosures referenced via public regulatory wires, company earnings releases and call transcripts, CMS Medicare Advantage rate notices and Stars programme documentation, and state Medicaid procurement releases where contracts are awarded.
Key sources
- Investor Relations | Investor Relations | Humana Inc.
- Humana (HUM) Earnings Date and Reports 2026 - MarketBeat
- Financial Press Releases | Investor Relations | Humana Inc.
- Press releases - Humana
- Humana (HUM) Stock Price & Overview - Stock Analysis
- Humana Inc. (HUM) - Yahoo Finance
- Humana Reports First Quarter 2026 Financial Results; Affirms Full Year ...
- Humana (HUM) earnings Q2 2026
- Humana (HUM) Q2 Earnings and Revenues Top Estimates
- Humana (HUM) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
Data correct as of 2026-08-01.